nodes	percent_of_prediction	percent_of_DWPC	metapath
Gabapentin—ADORA1—Pentoxifylline—systemic scleroderma	0.661	1	CbGbCtD
Gabapentin—Chest pain—Mycophenolate mofetil—systemic scleroderma	9.41e-05	0.000278	CcSEcCtD
Gabapentin—Arthralgia—Mycophenolate mofetil—systemic scleroderma	9.41e-05	0.000278	CcSEcCtD
Gabapentin—Myocardial infarction—Prednisone—systemic scleroderma	9.39e-05	0.000277	CcSEcCtD
Gabapentin—Neuropathy peripheral—Prednisone—systemic scleroderma	9.39e-05	0.000277	CcSEcCtD
Gabapentin—Breast disorder—Methotrexate—systemic scleroderma	9.39e-05	0.000277	CcSEcCtD
Gabapentin—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	9.38e-05	0.000277	CcSEcCtD
Gabapentin—Anxiety—Mycophenolate mofetil—systemic scleroderma	9.37e-05	0.000277	CcSEcCtD
Gabapentin—Hypersensitivity—Azathioprine—systemic scleroderma	9.34e-05	0.000276	CcSEcCtD
Gabapentin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	9.34e-05	0.000276	CcSEcCtD
Gabapentin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	9.34e-05	0.000276	CcSEcCtD
Gabapentin—Insomnia—Lisinopril—systemic scleroderma	9.31e-05	0.000275	CcSEcCtD
Gabapentin—Discomfort—Mycophenolate mofetil—systemic scleroderma	9.29e-05	0.000274	CcSEcCtD
Gabapentin—Paraesthesia—Lisinopril—systemic scleroderma	9.24e-05	0.000273	CcSEcCtD
Gabapentin—Vomiting—Captopril—systemic scleroderma	9.24e-05	0.000273	CcSEcCtD
Gabapentin—Dry mouth—Mycophenolate mofetil—systemic scleroderma	9.2e-05	0.000272	CcSEcCtD
Gabapentin—Dyspnoea—Lisinopril—systemic scleroderma	9.17e-05	0.000271	CcSEcCtD
Gabapentin—Rash—Captopril—systemic scleroderma	9.16e-05	0.000271	CcSEcCtD
Gabapentin—Dermatitis—Captopril—systemic scleroderma	9.15e-05	0.00027	CcSEcCtD
Gabapentin—Somnolence—Lisinopril—systemic scleroderma	9.15e-05	0.00027	CcSEcCtD
Gabapentin—Headache—Captopril—systemic scleroderma	9.1e-05	0.000269	CcSEcCtD
Gabapentin—Confusional state—Mycophenolate mofetil—systemic scleroderma	9.09e-05	0.000268	CcSEcCtD
Gabapentin—Dyspepsia—Lisinopril—systemic scleroderma	9.06e-05	0.000267	CcSEcCtD
Gabapentin—Abdominal pain—Mycophenolic acid—systemic scleroderma	9.03e-05	0.000267	CcSEcCtD
Gabapentin—Body temperature increased—Mycophenolic acid—systemic scleroderma	9.03e-05	0.000267	CcSEcCtD
Gabapentin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	9.02e-05	0.000266	CcSEcCtD
Gabapentin—Oedema—Mycophenolate mofetil—systemic scleroderma	9.02e-05	0.000266	CcSEcCtD
Gabapentin—Asthma—Methotrexate—systemic scleroderma	8.98e-05	0.000265	CcSEcCtD
Gabapentin—Infection—Mycophenolate mofetil—systemic scleroderma	8.96e-05	0.000264	CcSEcCtD
Gabapentin—Decreased appetite—Lisinopril—systemic scleroderma	8.95e-05	0.000264	CcSEcCtD
Gabapentin—Eosinophilia—Methotrexate—systemic scleroderma	8.89e-05	0.000263	CcSEcCtD
Gabapentin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	8.88e-05	0.000262	CcSEcCtD
Gabapentin—Fatigue—Lisinopril—systemic scleroderma	8.87e-05	0.000262	CcSEcCtD
Gabapentin—Shock—Mycophenolate mofetil—systemic scleroderma	8.87e-05	0.000262	CcSEcCtD
Gabapentin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	8.84e-05	0.000261	CcSEcCtD
Gabapentin—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	8.83e-05	0.000261	CcSEcCtD
Gabapentin—Hypersensitivity—Leflunomide—systemic scleroderma	8.82e-05	0.000261	CcSEcCtD
Gabapentin—Pancreatitis—Methotrexate—systemic scleroderma	8.81e-05	0.00026	CcSEcCtD
Gabapentin—Constipation—Lisinopril—systemic scleroderma	8.8e-05	0.00026	CcSEcCtD
Gabapentin—Pain—Lisinopril—systemic scleroderma	8.8e-05	0.00026	CcSEcCtD
Gabapentin—Tachycardia—Mycophenolate mofetil—systemic scleroderma	8.8e-05	0.00026	CcSEcCtD
Gabapentin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	8.76e-05	0.000259	CcSEcCtD
Gabapentin—Bradycardia—Prednisone—systemic scleroderma	8.76e-05	0.000259	CcSEcCtD
Gabapentin—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	8.72e-05	0.000257	CcSEcCtD
Gabapentin—Diarrhoea—Azathioprine—systemic scleroderma	8.68e-05	0.000256	CcSEcCtD
Gabapentin—Nausea—Captopril—systemic scleroderma	8.63e-05	0.000255	CcSEcCtD
Gabapentin—Haemorrhage—Prednisone—systemic scleroderma	8.6e-05	0.000254	CcSEcCtD
Gabapentin—Anorexia—Mycophenolate mofetil—systemic scleroderma	8.59e-05	0.000254	CcSEcCtD
Gabapentin—Asthenia—Leflunomide—systemic scleroderma	8.59e-05	0.000254	CcSEcCtD
Gabapentin—Hallucination—Prednisone—systemic scleroderma	8.56e-05	0.000253	CcSEcCtD
Gabapentin—Feeling abnormal—Lisinopril—systemic scleroderma	8.48e-05	0.00025	CcSEcCtD
Gabapentin—Pruritus—Leflunomide—systemic scleroderma	8.47e-05	0.00025	CcSEcCtD
Gabapentin—Connective tissue disorder—Prednisone—systemic scleroderma	8.45e-05	0.00025	CcSEcCtD
Gabapentin—Hypotension—Mycophenolate mofetil—systemic scleroderma	8.42e-05	0.000249	CcSEcCtD
Gabapentin—Gastrointestinal pain—Lisinopril—systemic scleroderma	8.41e-05	0.000248	CcSEcCtD
Gabapentin—Dysuria—Methotrexate—systemic scleroderma	8.4e-05	0.000248	CcSEcCtD
Gabapentin—Dizziness—Azathioprine—systemic scleroderma	8.39e-05	0.000248	CcSEcCtD
Gabapentin—Upper respiratory tract infection—Methotrexate—systemic scleroderma	8.35e-05	0.000246	CcSEcCtD
Gabapentin—Erectile dysfunction—Methotrexate—systemic scleroderma	8.27e-05	0.000244	CcSEcCtD
Gabapentin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	8.21e-05	0.000243	CcSEcCtD
Gabapentin—Photosensitivity reaction—Methotrexate—systemic scleroderma	8.2e-05	0.000242	CcSEcCtD
Gabapentin—Asthenia—Mycophenolic acid—systemic scleroderma	8.2e-05	0.000242	CcSEcCtD
Gabapentin—Diarrhoea—Leflunomide—systemic scleroderma	8.19e-05	0.000242	CcSEcCtD
Gabapentin—Urticaria—Lisinopril—systemic scleroderma	8.17e-05	0.000241	CcSEcCtD
Gabapentin—Insomnia—Mycophenolate mofetil—systemic scleroderma	8.15e-05	0.000241	CcSEcCtD
Gabapentin—Abdominal pain—Lisinopril—systemic scleroderma	8.13e-05	0.00024	CcSEcCtD
Gabapentin—Body temperature increased—Lisinopril—systemic scleroderma	8.13e-05	0.00024	CcSEcCtD
Gabapentin—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	8.1e-05	0.000239	CcSEcCtD
Gabapentin—Pruritus—Mycophenolic acid—systemic scleroderma	8.08e-05	0.000239	CcSEcCtD
Gabapentin—Vomiting—Azathioprine—systemic scleroderma	8.06e-05	0.000238	CcSEcCtD
Gabapentin—Pneumonia—Methotrexate—systemic scleroderma	8.06e-05	0.000238	CcSEcCtD
Gabapentin—Eye disorder—Prednisone—systemic scleroderma	8.04e-05	0.000237	CcSEcCtD
Gabapentin—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	8.04e-05	0.000237	CcSEcCtD
Gabapentin—Somnolence—Mycophenolate mofetil—systemic scleroderma	8.02e-05	0.000237	CcSEcCtD
Gabapentin—Drowsiness—Methotrexate—systemic scleroderma	8.01e-05	0.000236	CcSEcCtD
Gabapentin—Infestation—Methotrexate—systemic scleroderma	8.01e-05	0.000236	CcSEcCtD
Gabapentin—Infestation NOS—Methotrexate—systemic scleroderma	8.01e-05	0.000236	CcSEcCtD
Gabapentin—Rash—Azathioprine—systemic scleroderma	8e-05	0.000236	CcSEcCtD
Gabapentin—Dermatitis—Azathioprine—systemic scleroderma	7.99e-05	0.000236	CcSEcCtD
Gabapentin—Depression—Methotrexate—systemic scleroderma	7.99e-05	0.000236	CcSEcCtD
Gabapentin—Headache—Azathioprine—systemic scleroderma	7.94e-05	0.000235	CcSEcCtD
Gabapentin—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	7.94e-05	0.000234	CcSEcCtD
Gabapentin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	7.94e-05	0.000234	CcSEcCtD
Gabapentin—Dizziness—Leflunomide—systemic scleroderma	7.92e-05	0.000234	CcSEcCtD
Gabapentin—Renal failure—Methotrexate—systemic scleroderma	7.87e-05	0.000232	CcSEcCtD
Gabapentin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	7.84e-05	0.000231	CcSEcCtD
Gabapentin—Diarrhoea—Mycophenolic acid—systemic scleroderma	7.82e-05	0.000231	CcSEcCtD
Gabapentin—Stomatitis—Methotrexate—systemic scleroderma	7.81e-05	0.000231	CcSEcCtD
Gabapentin—Conjunctivitis—Methotrexate—systemic scleroderma	7.78e-05	0.00023	CcSEcCtD
Gabapentin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	7.78e-05	0.00023	CcSEcCtD
Gabapentin—Immune system disorder—Prednisone—systemic scleroderma	7.77e-05	0.000229	CcSEcCtD
Gabapentin—Constipation—Mycophenolate mofetil—systemic scleroderma	7.71e-05	0.000228	CcSEcCtD
Gabapentin—Pain—Mycophenolate mofetil—systemic scleroderma	7.71e-05	0.000228	CcSEcCtD
Gabapentin—Sweating—Methotrexate—systemic scleroderma	7.68e-05	0.000227	CcSEcCtD
Gabapentin—Haematuria—Methotrexate—systemic scleroderma	7.64e-05	0.000225	CcSEcCtD
Gabapentin—Vomiting—Leflunomide—systemic scleroderma	7.61e-05	0.000225	CcSEcCtD
Gabapentin—Alopecia—Prednisone—systemic scleroderma	7.6e-05	0.000224	CcSEcCtD
Gabapentin—Hypersensitivity—Lisinopril—systemic scleroderma	7.58e-05	0.000224	CcSEcCtD
Gabapentin—Hepatobiliary disease—Methotrexate—systemic scleroderma	7.57e-05	0.000224	CcSEcCtD
Gabapentin—Dizziness—Mycophenolic acid—systemic scleroderma	7.55e-05	0.000223	CcSEcCtD
Gabapentin—Epistaxis—Methotrexate—systemic scleroderma	7.55e-05	0.000223	CcSEcCtD
Gabapentin—Rash—Leflunomide—systemic scleroderma	7.55e-05	0.000223	CcSEcCtD
Gabapentin—Dermatitis—Leflunomide—systemic scleroderma	7.54e-05	0.000223	CcSEcCtD
Gabapentin—Mental disorder—Prednisone—systemic scleroderma	7.54e-05	0.000223	CcSEcCtD
Gabapentin—Nausea—Azathioprine—systemic scleroderma	7.53e-05	0.000222	CcSEcCtD
Gabapentin—Headache—Leflunomide—systemic scleroderma	7.5e-05	0.000222	CcSEcCtD
Gabapentin—Erythema—Prednisone—systemic scleroderma	7.49e-05	0.000221	CcSEcCtD
Gabapentin—Malnutrition—Prednisone—systemic scleroderma	7.49e-05	0.000221	CcSEcCtD
Gabapentin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	7.43e-05	0.000219	CcSEcCtD
Gabapentin—Asthenia—Lisinopril—systemic scleroderma	7.38e-05	0.000218	CcSEcCtD
Gabapentin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	7.37e-05	0.000218	CcSEcCtD
Gabapentin—Pruritus—Lisinopril—systemic scleroderma	7.28e-05	0.000215	CcSEcCtD
Gabapentin—Vomiting—Mycophenolic acid—systemic scleroderma	7.26e-05	0.000214	CcSEcCtD
Gabapentin—Rash—Mycophenolic acid—systemic scleroderma	7.2e-05	0.000213	CcSEcCtD
Gabapentin—Dermatitis—Mycophenolic acid—systemic scleroderma	7.2e-05	0.000213	CcSEcCtD
Gabapentin—Haemorrhage—Methotrexate—systemic scleroderma	7.19e-05	0.000212	CcSEcCtD
Gabapentin—Hepatitis—Methotrexate—systemic scleroderma	7.19e-05	0.000212	CcSEcCtD
Gabapentin—Urticaria—Mycophenolate mofetil—systemic scleroderma	7.16e-05	0.000212	CcSEcCtD
Gabapentin—Headache—Mycophenolic acid—systemic scleroderma	7.16e-05	0.000211	CcSEcCtD
Gabapentin—Pharyngitis—Methotrexate—systemic scleroderma	7.14e-05	0.000211	CcSEcCtD
Gabapentin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	7.13e-05	0.00021	CcSEcCtD
Gabapentin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	7.13e-05	0.00021	CcSEcCtD
Gabapentin—Nausea—Leflunomide—systemic scleroderma	7.11e-05	0.00021	CcSEcCtD
Gabapentin—Urinary tract disorder—Methotrexate—systemic scleroderma	7.1e-05	0.00021	CcSEcCtD
Gabapentin—Vision blurred—Prednisone—systemic scleroderma	7.06e-05	0.000208	CcSEcCtD
Gabapentin—Urethral disorder—Methotrexate—systemic scleroderma	7.05e-05	0.000208	CcSEcCtD
Gabapentin—Diarrhoea—Lisinopril—systemic scleroderma	7.04e-05	0.000208	CcSEcCtD
Gabapentin—Ill-defined disorder—Prednisone—systemic scleroderma	6.95e-05	0.000205	CcSEcCtD
Gabapentin—Visual impairment—Methotrexate—systemic scleroderma	6.93e-05	0.000205	CcSEcCtD
Gabapentin—Anaemia—Prednisone—systemic scleroderma	6.92e-05	0.000204	CcSEcCtD
Gabapentin—Agitation—Prednisone—systemic scleroderma	6.88e-05	0.000203	CcSEcCtD
Gabapentin—Angioedema—Prednisone—systemic scleroderma	6.84e-05	0.000202	CcSEcCtD
Gabapentin—Dizziness—Lisinopril—systemic scleroderma	6.8e-05	0.000201	CcSEcCtD
Gabapentin—Erythema multiforme—Methotrexate—systemic scleroderma	6.8e-05	0.000201	CcSEcCtD
Gabapentin—Nausea—Mycophenolic acid—systemic scleroderma	6.79e-05	0.0002	CcSEcCtD
Gabapentin—Malaise—Prednisone—systemic scleroderma	6.75e-05	0.000199	CcSEcCtD
Gabapentin—Vertigo—Prednisone—systemic scleroderma	6.73e-05	0.000199	CcSEcCtD
Gabapentin—Eye disorder—Methotrexate—systemic scleroderma	6.72e-05	0.000198	CcSEcCtD
Gabapentin—Syncope—Prednisone—systemic scleroderma	6.72e-05	0.000198	CcSEcCtD
Gabapentin—Tinnitus—Methotrexate—systemic scleroderma	6.7e-05	0.000198	CcSEcCtD
Gabapentin—Cardiac disorder—Methotrexate—systemic scleroderma	6.67e-05	0.000197	CcSEcCtD
Gabapentin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	6.64e-05	0.000196	CcSEcCtD
Gabapentin—Loss of consciousness—Prednisone—systemic scleroderma	6.58e-05	0.000194	CcSEcCtD
Gabapentin—Vomiting—Lisinopril—systemic scleroderma	6.54e-05	0.000193	CcSEcCtD
Gabapentin—Immune system disorder—Methotrexate—systemic scleroderma	6.49e-05	0.000192	CcSEcCtD
Gabapentin—Rash—Lisinopril—systemic scleroderma	6.49e-05	0.000192	CcSEcCtD
Gabapentin—Convulsion—Prednisone—systemic scleroderma	6.49e-05	0.000192	CcSEcCtD
Gabapentin—Dermatitis—Lisinopril—systemic scleroderma	6.48e-05	0.000191	CcSEcCtD
Gabapentin—Mediastinal disorder—Methotrexate—systemic scleroderma	6.48e-05	0.000191	CcSEcCtD
Gabapentin—Asthenia—Mycophenolate mofetil—systemic scleroderma	6.47e-05	0.000191	CcSEcCtD
Gabapentin—Hypertension—Prednisone—systemic scleroderma	6.47e-05	0.000191	CcSEcCtD
Gabapentin—Chills—Methotrexate—systemic scleroderma	6.45e-05	0.00019	CcSEcCtD
Gabapentin—Headache—Lisinopril—systemic scleroderma	6.45e-05	0.00019	CcSEcCtD
Gabapentin—Pruritus—Mycophenolate mofetil—systemic scleroderma	6.38e-05	0.000188	CcSEcCtD
Gabapentin—Myalgia—Prednisone—systemic scleroderma	6.38e-05	0.000188	CcSEcCtD
Gabapentin—Arthralgia—Prednisone—systemic scleroderma	6.38e-05	0.000188	CcSEcCtD
Gabapentin—Anxiety—Prednisone—systemic scleroderma	6.35e-05	0.000188	CcSEcCtD
Gabapentin—Alopecia—Methotrexate—systemic scleroderma	6.35e-05	0.000188	CcSEcCtD
Gabapentin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	6.33e-05	0.000187	CcSEcCtD
Gabapentin—Discomfort—Prednisone—systemic scleroderma	6.3e-05	0.000186	CcSEcCtD
Gabapentin—Mental disorder—Methotrexate—systemic scleroderma	6.3e-05	0.000186	CcSEcCtD
Gabapentin—Malnutrition—Methotrexate—systemic scleroderma	6.26e-05	0.000185	CcSEcCtD
Gabapentin—Erythema—Methotrexate—systemic scleroderma	6.26e-05	0.000185	CcSEcCtD
Gabapentin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	6.17e-05	0.000182	CcSEcCtD
Gabapentin—Dysgeusia—Methotrexate—systemic scleroderma	6.13e-05	0.000181	CcSEcCtD
Gabapentin—Nausea—Lisinopril—systemic scleroderma	6.11e-05	0.00018	CcSEcCtD
Gabapentin—Anaphylactic shock—Prednisone—systemic scleroderma	6.11e-05	0.00018	CcSEcCtD
Gabapentin—Oedema—Prednisone—systemic scleroderma	6.11e-05	0.00018	CcSEcCtD
Gabapentin—Infection—Prednisone—systemic scleroderma	6.07e-05	0.000179	CcSEcCtD
Gabapentin—Back pain—Methotrexate—systemic scleroderma	6.05e-05	0.000179	CcSEcCtD
Gabapentin—Shock—Prednisone—systemic scleroderma	6.01e-05	0.000178	CcSEcCtD
Gabapentin—Nervous system disorder—Prednisone—systemic scleroderma	5.99e-05	0.000177	CcSEcCtD
Gabapentin—Tachycardia—Prednisone—systemic scleroderma	5.96e-05	0.000176	CcSEcCtD
Gabapentin—Dizziness—Mycophenolate mofetil—systemic scleroderma	5.96e-05	0.000176	CcSEcCtD
Gabapentin—Skin disorder—Prednisone—systemic scleroderma	5.94e-05	0.000175	CcSEcCtD
Gabapentin—Hyperhidrosis—Prednisone—systemic scleroderma	5.91e-05	0.000174	CcSEcCtD
Gabapentin—Vision blurred—Methotrexate—systemic scleroderma	5.9e-05	0.000174	CcSEcCtD
Gabapentin—Anorexia—Prednisone—systemic scleroderma	5.83e-05	0.000172	CcSEcCtD
Gabapentin—Ill-defined disorder—Methotrexate—systemic scleroderma	5.81e-05	0.000171	CcSEcCtD
Gabapentin—Anaemia—Methotrexate—systemic scleroderma	5.78e-05	0.000171	CcSEcCtD
Gabapentin—Vomiting—Mycophenolate mofetil—systemic scleroderma	5.73e-05	0.000169	CcSEcCtD
Gabapentin—Rash—Mycophenolate mofetil—systemic scleroderma	5.68e-05	0.000168	CcSEcCtD
Gabapentin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	5.68e-05	0.000168	CcSEcCtD
Gabapentin—Headache—Mycophenolate mofetil—systemic scleroderma	5.65e-05	0.000167	CcSEcCtD
Gabapentin—Malaise—Methotrexate—systemic scleroderma	5.64e-05	0.000167	CcSEcCtD
Gabapentin—Vertigo—Methotrexate—systemic scleroderma	5.62e-05	0.000166	CcSEcCtD
Gabapentin—Leukopenia—Methotrexate—systemic scleroderma	5.6e-05	0.000165	CcSEcCtD
Gabapentin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	5.57e-05	0.000164	CcSEcCtD
Gabapentin—Insomnia—Prednisone—systemic scleroderma	5.53e-05	0.000163	CcSEcCtD
Gabapentin—Paraesthesia—Prednisone—systemic scleroderma	5.49e-05	0.000162	CcSEcCtD
Gabapentin—Cough—Methotrexate—systemic scleroderma	5.46e-05	0.000161	CcSEcCtD
Gabapentin—Convulsion—Methotrexate—systemic scleroderma	5.42e-05	0.00016	CcSEcCtD
Gabapentin—Dyspepsia—Prednisone—systemic scleroderma	5.38e-05	0.000159	CcSEcCtD
Gabapentin—Nausea—Mycophenolate mofetil—systemic scleroderma	5.36e-05	0.000158	CcSEcCtD
Gabapentin—Chest pain—Methotrexate—systemic scleroderma	5.33e-05	0.000157	CcSEcCtD
Gabapentin—Arthralgia—Methotrexate—systemic scleroderma	5.33e-05	0.000157	CcSEcCtD
Gabapentin—Myalgia—Methotrexate—systemic scleroderma	5.33e-05	0.000157	CcSEcCtD
Gabapentin—Decreased appetite—Prednisone—systemic scleroderma	5.31e-05	0.000157	CcSEcCtD
Gabapentin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	5.29e-05	0.000156	CcSEcCtD
Gabapentin—Fatigue—Prednisone—systemic scleroderma	5.27e-05	0.000156	CcSEcCtD
Gabapentin—Discomfort—Methotrexate—systemic scleroderma	5.26e-05	0.000155	CcSEcCtD
Gabapentin—Constipation—Prednisone—systemic scleroderma	5.23e-05	0.000154	CcSEcCtD
Gabapentin—Confusional state—Methotrexate—systemic scleroderma	5.15e-05	0.000152	CcSEcCtD
Gabapentin—Anaphylactic shock—Methotrexate—systemic scleroderma	5.11e-05	0.000151	CcSEcCtD
Gabapentin—Infection—Methotrexate—systemic scleroderma	5.07e-05	0.00015	CcSEcCtD
Gabapentin—Feeling abnormal—Prednisone—systemic scleroderma	5.04e-05	0.000149	CcSEcCtD
Gabapentin—Nervous system disorder—Methotrexate—systemic scleroderma	5.01e-05	0.000148	CcSEcCtD
Gabapentin—Thrombocytopenia—Methotrexate—systemic scleroderma	5e-05	0.000148	CcSEcCtD
Gabapentin—Gastrointestinal pain—Prednisone—systemic scleroderma	5e-05	0.000148	CcSEcCtD
Gabapentin—Skin disorder—Methotrexate—systemic scleroderma	4.96e-05	0.000146	CcSEcCtD
Gabapentin—Hyperhidrosis—Methotrexate—systemic scleroderma	4.94e-05	0.000146	CcSEcCtD
Gabapentin—Anorexia—Methotrexate—systemic scleroderma	4.87e-05	0.000144	CcSEcCtD
Gabapentin—Urticaria—Prednisone—systemic scleroderma	4.86e-05	0.000143	CcSEcCtD
Gabapentin—Body temperature increased—Prednisone—systemic scleroderma	4.83e-05	0.000143	CcSEcCtD
Gabapentin—Abdominal pain—Prednisone—systemic scleroderma	4.83e-05	0.000143	CcSEcCtD
Gabapentin—Hypotension—Methotrexate—systemic scleroderma	4.77e-05	0.000141	CcSEcCtD
Gabapentin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	4.65e-05	0.000137	CcSEcCtD
Gabapentin—Insomnia—Methotrexate—systemic scleroderma	4.62e-05	0.000136	CcSEcCtD
Gabapentin—Paraesthesia—Methotrexate—systemic scleroderma	4.59e-05	0.000135	CcSEcCtD
Gabapentin—Dyspnoea—Methotrexate—systemic scleroderma	4.55e-05	0.000134	CcSEcCtD
Gabapentin—Somnolence—Methotrexate—systemic scleroderma	4.54e-05	0.000134	CcSEcCtD
Gabapentin—Hypersensitivity—Prednisone—systemic scleroderma	4.5e-05	0.000133	CcSEcCtD
Gabapentin—Dyspepsia—Methotrexate—systemic scleroderma	4.5e-05	0.000133	CcSEcCtD
Gabapentin—Decreased appetite—Methotrexate—systemic scleroderma	4.44e-05	0.000131	CcSEcCtD
Gabapentin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	4.41e-05	0.00013	CcSEcCtD
Gabapentin—Fatigue—Methotrexate—systemic scleroderma	4.4e-05	0.00013	CcSEcCtD
Gabapentin—Asthenia—Prednisone—systemic scleroderma	4.38e-05	0.000129	CcSEcCtD
Gabapentin—Pain—Methotrexate—systemic scleroderma	4.37e-05	0.000129	CcSEcCtD
Gabapentin—Pruritus—Prednisone—systemic scleroderma	4.32e-05	0.000128	CcSEcCtD
Gabapentin—Feeling abnormal—Methotrexate—systemic scleroderma	4.21e-05	0.000124	CcSEcCtD
Gabapentin—Diarrhoea—Prednisone—systemic scleroderma	4.18e-05	0.000123	CcSEcCtD
Gabapentin—Gastrointestinal pain—Methotrexate—systemic scleroderma	4.18e-05	0.000123	CcSEcCtD
Gabapentin—Urticaria—Methotrexate—systemic scleroderma	4.06e-05	0.00012	CcSEcCtD
Gabapentin—Dizziness—Prednisone—systemic scleroderma	4.04e-05	0.000119	CcSEcCtD
Gabapentin—Abdominal pain—Methotrexate—systemic scleroderma	4.04e-05	0.000119	CcSEcCtD
Gabapentin—Body temperature increased—Methotrexate—systemic scleroderma	4.04e-05	0.000119	CcSEcCtD
Gabapentin—Vomiting—Prednisone—systemic scleroderma	3.89e-05	0.000115	CcSEcCtD
Gabapentin—Rash—Prednisone—systemic scleroderma	3.85e-05	0.000114	CcSEcCtD
Gabapentin—Dermatitis—Prednisone—systemic scleroderma	3.85e-05	0.000114	CcSEcCtD
Gabapentin—Headache—Prednisone—systemic scleroderma	3.83e-05	0.000113	CcSEcCtD
Gabapentin—Hypersensitivity—Methotrexate—systemic scleroderma	3.76e-05	0.000111	CcSEcCtD
Gabapentin—Asthenia—Methotrexate—systemic scleroderma	3.66e-05	0.000108	CcSEcCtD
Gabapentin—Nausea—Prednisone—systemic scleroderma	3.63e-05	0.000107	CcSEcCtD
Gabapentin—Pruritus—Methotrexate—systemic scleroderma	3.61e-05	0.000107	CcSEcCtD
Gabapentin—Diarrhoea—Methotrexate—systemic scleroderma	3.49e-05	0.000103	CcSEcCtD
Gabapentin—Dizziness—Methotrexate—systemic scleroderma	3.38e-05	9.97e-05	CcSEcCtD
Gabapentin—Vomiting—Methotrexate—systemic scleroderma	3.25e-05	9.59e-05	CcSEcCtD
Gabapentin—Rash—Methotrexate—systemic scleroderma	3.22e-05	9.51e-05	CcSEcCtD
Gabapentin—Dermatitis—Methotrexate—systemic scleroderma	3.22e-05	9.5e-05	CcSEcCtD
Gabapentin—Headache—Methotrexate—systemic scleroderma	3.2e-05	9.45e-05	CcSEcCtD
Gabapentin—Nausea—Methotrexate—systemic scleroderma	3.03e-05	8.96e-05	CcSEcCtD
